The FDA has approved a FET-PET imaging agent, to help characterize recurrent or progressive glioma from treatment-related changes.
|Articles|December 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 12
- Volume 16
- Issue 12
Encouraging Avastin results in glioblastoma multiforme
Encouraging Avastin results in glioblastoma multiforme
Advertisement
DALLAS—Phase II data showed 6-month progression-free survival in 36% of relapsed glioblastoma patients given Avastin (bevacizumab) alone and 51% given Avastin plus irinotecan (Camptosar), compared with historical estimates of 15%. UCLA's Timothy Cloughesy, MD, reported the findings at the Society for Neuro-Oncology annual meeting.
Articles in this issue
almost 19 years ago
Third-line single-agent cetuximab ups overall survivalalmost 19 years ago
Modern multislice CT propels pancreas imaging forwardalmost 19 years ago
Sorafenib gets ok for liver canceralmost 19 years ago
Celgene to acquire Pharmionalmost 19 years ago
Novacea halts ASCENT-2 trialalmost 19 years ago
RT/temozolomide raises possibility of cure in glioblastomaalmost 19 years ago
Brachytherapy as effective in younger as in older menalmost 19 years ago
MMA not harming patientsalmost 19 years ago
Kinase inhibitor may prevent RT-induced lung injuryalmost 19 years ago
FDA approves lower starting dose for dasatinib for CMLAdvertisement
Related to this article
Josef Vymazal, MD, discussed how gadopiclenol’s pharmacokinetics may explain why delayed double-dose imaging outperformed delayed single-dose imaging for detecting brain metastases.
Josef Vymazal, MD, discussed a randomized study showing delayed double-dose gadopiclenol significantly improved detection of small brain metastases compared with standard imaging.
Josef Vymazal, MD, explained why high-relaxivity contrast agents are critical for detecting small brain metastases, despite weaker agents remaining suitable for other indications.
The first patient has been dosed in a phase 2 trial evaluating paxalisib plus gemcitabine in children and young adults with recurrent atypical teratoid/rhabdoid tumor.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
4
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
5